Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on May 6, 2019, regarding an event that occurred on April 30, 2019. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol "CUR".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Appointment: The Board of Directors appointed David Mazzo, PhD, effective June 12, 2019.
- Director Retirement: Stanley Westreich is retiring from the Board on the same effective date.
- Board Composition: The Board will continue to have seven (7) acting directors following the transition.
- Term Details: Dr. Mazzo will serve as a Class II director until the 2022 annual meeting of shareholders or until resignation, removal, or appointment of a successor.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The report notes that Dr. Mazzo will enter into the Company's standard indemnification agreement and will participate in the non-executive board compensation plan previously described in a June 27, 2017, Form 8-K. No risks, contingencies, or unusual items were disclosed in this specific report.
Important Facts for Investors to Verify
- Confirm the effective date of the board transition (June 12, 2019) and the resulting board size.
- Review the attached press release (Exhibit 99.01) for additional context on Dr. Mazzo's qualifications.
- Verify the terms of the non-executive board compensation plan referenced from the 2017 filing.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.